Farxiga Data Change Heart Failure Treatment Outlook
DAPA-HF data on AstraZeneca’s SGLT-2 inhibitor dapagliflozin as a treatment for heart failure in both diabetics and non-diabetics won spontaneous applause at ESC.
You may also be interested in...
Cardiologists in Europe who have so far been unwilling to embrace the SGLT2 class now have two drugs approved for heart failure with reduced ejection fraction, with Jardiance soon to join Farxiga on the market, potentially attractive options especially for their diabetic patients.
AstraZeneca's biopharmaceuticals president Ruud Dobber tells Scrip that the price for Farxiga in the heart failure indication should reflect its potential to improve survival and reduce the need for hospitalization.